Key Highlights

  • Osteopore(ASX:OSX) and DKSH Singapore have agreed to conclude the exclusive orthopaedic products sales arrangement effective 31 December 2026
  • Osteopore International will assume direct sales and Marketing of the Business from 1 January 2027
  • The transition follows Osteopore's establishment of 3D printing services and the upcoming launch of injectable regenerative bone fillers
  • Osteopore's products have been deployed in all major Singapore public hospitals

Osteopore Limited(ASX:OSX) announced on 2 November 2026 that it will assume direct responsibility for the sales and marketing of its orthopaedic products in Singapore, following the agreed conclusion of its exclusive arrangement with DKSH Singapore Pte Ltd, effective 31 December 2026.

The Australian-Singaporean regenerative medicine company, which specialises in 3D-printed biomimetic and bioresorbable implants, originally signed a five-year exclusive contract sales and marketing agreement with DKSH in November 2024.

Why Is Osteopore Moving to Direct Sales?

The company stated that the decision to manage the Singapore business directly stems from the need to focus on the orthopaedic business in its home market, where direct customer interaction is viewed as a driver of adoption and innovation.

The timing aligns with two recent product developments targeting the same customer group: the establishment of Osteopore's 3D printing services, announced in February 2026, and the upcoming introduction of injectable regenerative bone fillers, following an agreement announced in March 2026. Managing all three offerings through a single direct sales and marketing team is intended to streamline customer interaction and experience.

What Market Position Has Osteopore Built?

Over the past two years with DKSH's support, Osteopore's orthopaedic products have been deployed in all major Singapore public hospitals. The products have also been adopted by orthopaedic surgeons offering surgical treatments for knee preservation and bone reconstruction in cases of substantial bone loss.

The company stated that it has recently strengthened its sales and marketing team and is now positioned to support the business and its customers directly in Singapore.

What Is Osteopore's Technology?

Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. The polymer scaffolds naturally dissolve over time, allowing only natural and healthy bone tissue to regrow. This approach is designed to reduce post-surgery complications commonly associated with permanent bone implants.

Where Does Osteopore Stand Going Forward?

CEO Dr Yujing Lim noted that Singapore represents a key market for the company as its home base, and that the business has reached a phase of growth requiring dedicated resources. The direct sales model is expected to support closer customer relationships as the company expands its product range.